Jeremy Bender Sells 12,048 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN traded up $0.20 during mid-day trading on Friday, hitting $12.43. The company’s stock had a trading volume of 758,249 shares, compared to its average volume of 981,378. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.13 and a 1 year high of $18.07. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. The business’s fifty day moving average is $12.37 and its two-hundred day moving average is $13.47.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently modified their holdings of the company. First Turn Management LLC purchased a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $13,204,000. GSA Capital Partners LLP purchased a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $825,000. Algert Global LLC boosted its stake in shares of Day One Biopharmaceuticals by 248.8% during the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after acquiring an additional 50,990 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $866,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after acquiring an additional 64,700 shares in the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DAWN has been the topic of a number of research analyst reports. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Finally, The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, February 10th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.